Angela Maria Spinola-Castro

Angela Maria Spinola-Castro

Auto-generated profile, based on publicly available information

Angela Maria Spinola-Castro

Universidade Federal de São Paulo, São Paulo SP, Brazil

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
VBVinícius Nahime Brito
Vinícius Nahime Brito
ASAngela Maria Spinola-Castro
Angela Maria Spinola-Castro
CKCristiane Kochi
Cristiane Kochi
CKCristiane Kopacek
Cristiane Kopacek
PSPaulo César Alves da Silva
Paulo César Alves da Silva
Gil Guerra-JuniorGil Guerra-Junior
Gil Guerra-Junior
Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72

1 March 2009 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
ASAdriana Aparecida Siviero-Miachon
Adriana Aparecida Siviero-Miachon
ASAngela Maria Spinola-Castro
Angela Maria Spinola-Castro
Gil Guerra-JuniorGil Guerra-Junior
Gil Guerra-Junior
As childhood cancer treatment has become more effective, survival rates have improved, and a number of complications have been described while many of these patients reach adulthood. Obesity is a well-recognized late effect, and its metabolic effects may lead to cardiovascular disease. Currently, studies concerning overweight have focused on acute lymphocytic leukemia and brain tumors, since they are at risk for hypothalamic-pituitary axis damage secondary to cancer therapies (cranial irradiation, chemotherapy, and brain surgery) or to primary tumor location. Obesity and cancer have metabolic syndrome features in common. Thus, it remains controversial if overweight is a cause or consequence of cancer, and to date additional mechanisms involving adipose tissue and hypothalamic derangements have been considered, comprising premature adiposity rebound, hyperinsulinemia, leptin regulation, and the role of peroxisome proliferator-activated receptor γ. Overall, further research is still necessary to better understand the relationship between adipogenesis and hypothalamic control deregulation following cancer therapy.

29 June 2018 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
PTPatrícia Débora Cavalcanti Tosta-Hernandez
Patrícia Débora Cavalcanti Tosta-Hernandez
ASAdriana Aparecida Siviero-Miachon
Adriana Aparecida Siviero-Miachon
NSNasjla Saba da Silva
Nasjla Saba da Silva
ACAndrea Cappellano
Andrea Cappellano
MPMarcelo de Medeiros Pinheiro
Marcelo de Medeiros Pinheiro
ASAngela Maria Spinola-Castro
Angela Maria Spinola-Castro
Craniopharyngioma is a sellar/suprasellar benign tumor whose aggressiveness may imply in endocrine disturbances (hypothalamic obesity and hormone deficiencies). Fifty-seven patients were evaluated according to clinical characteristics, hypothalamic involvement, type of treatment, anthropometric variables, adiposity indexes (body mass index Z score category at diagnosis and post-treatment, total body fat, visceral adipose tissue, and metabolic syndrome components) and analyzed through multiple regression and logistic models. Patients were stratified according to growth hormone deficiency and recombinant human growth hormone use. Mean ages at diagnosis and at study evaluation were 9.6 and 16.6 years old, respectively. A set of 43/57 (75.4%) patients presented with important hypothalamic involvement, 24/57 (42.1%) received surgical treatment and cranial radiotherapy, and 8/57 (14%) interferon-α exclusively. Fifty-five patients (96.5%) were considered growth hormone deficient, and 26/57 (45.6%) grew despite no recombinant human growth hormone replacement therapy. At diagnosis, 12/57 (21%) patients were obese, and 33/57 (57.9%) at study evaluation, and after 3.2 years (median) post first therapy. There was no influence of height Z score on body mass index Z score. Body mass index Z score at diagnosis positively influenced body mass index Z score, total body fat, waist circumference and the presence of the metabolic syndrome post-treatment. Replacement of recombinant human growth hormone decreased total body fat and visceral adipose tissue. Craniopharyngioma patients worsened body mass index Z score category 3.2 years (median) after first treatment. Body mass index Z score increased due to real weight gain, without height decrease. Replacement of recombinant human growth hormone had beneficial effect on adiposity. * Both authors contributed equally to this work

21 February 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
ASAdriana Aparecida Siviero-Miachon
Adriana Aparecida Siviero-Miachon
ASAngela Maria Spinola-Castro
Angela Maria Spinola-Castro
MLMaria Lúcia de Martino Lee
Maria Lúcia de Martino Lee
SASolange Andreoni
Solange Andreoni
BGBruno Geloneze
Bruno Geloneze
Gil Guerra-JuniorGil Guerra-Junior
Gil Guerra-Junior
Background: Advances in treatment of acute lymphocytic leukemia increased the likelihood of developing late treatment-associated effects, such as abdominal adiposity, increasing the risk of cardiovascular disease in this population. Cranial radiotherapy is one of the factors that might be involved in this process. The aim of this study was to determine the effect of cranial radiotherapy on adiposity indexes in survivors of acute lymphocytic leukemia. Methods: A comparative cross-sectional study of 56 acute lymphocytic leukemia survivors, chronological age between 15 and 24 years, assigned into two groups according to the exposure to cranial radiotherapy (25 irradiated and 31 non-irradiated), assessed according to body fat (dual energy X-ray absorptiometry), computed tomography scan-derived abdominal adipose tissue, lipid profile, and insulin resistance. Results: Cranial radiotherapy increased body fat and abdominal adipose tissue and altered lipid panel. Yet, lipids showed no clinical relevance so far. There were significantly more obese patients among those who received cranial radiotherapy (52% irradiated versus 22.6% non-irradiated), based on dual energy X-ray absorptiometry body fat measurements. Nonetheless, no association was observed between cranial radiotherapy and body mass index, waist circumference, waist-to-height ratio or insulin resistance. Conclusions: Adolescent and young adult survivors of childhood acute lymphocytic leukemia showed an increase in body fat and an alteration of fat distribution, which were related to cranial radiotherapy. Fat compartment modifications possibly indicate a disease of adipose tissue, and cranial radiotherapy imports in this process.

1 February 2012 in Early Human Development
Verified
Journal Article
Closed access
ABAlexandre Duarte Baldin
Alexandre Duarte Baldin
ASAdriana Aparecida Siviero-Miachon
Adriana Aparecida Siviero-Miachon
TFTatiana Fabbri
Tatiana Fabbri
SLSofia Helena Valente Lemos-Marini
Sofia Helena Valente Lemos-Marini
ASAngela Maria Spinola-Castro
Angela Maria Spinola-Castro
Gil Guerra-JuniorGil Guerra-Junior
Gil Guerra-Junior

14 December 2017 in Sexual Development
Verified
Journal Article
Closed access
RPReginaldo J. Petroli
Reginaldo J. Petroli
OHOlaf Hiort
Olaf Hiort
DSDagmar Struve
Dagmar Struve
JGJulia K. Gesing
Julia K. Gesing
FSFernanda C. Soardi
Fernanda C. Soardi
MMMaricilda Palandi De Mello
Maricilda Palandi De Mello
Androgens are responsible for the development and maintenance of male sex characteristics. Dysfunctions in androgen action due to mutations in the androgen receptor gene (AR) can lead to androgen insensitivity syndrome (AIS) that can be classified as mild (MAIS), partial (PAIS), or complete (CAIS). We have analyzed functional effects of p.Ser760Thr, p.Leu831Phe, p.Ile899Phe, p.Leu769Val, and p.Pro905Arg mutations and the combination p.Gln799Glu + p.Cys807Phe that were identified in patients with PAIS or CAIS. The p.Leu769Val and p.Pro905Arg mutations showed complete disruption of AR action under physiological hormone concentrations; however, they differed in high DHT concentrations especially in the N/C terminal interaction assay. Mutations p.Ser760Thr, p.Leu831Phe, p.Ile899Phe presented transactivation activities higher than 20% of the wild type in physiological hormone concentrations and increased with higher DHT concentrations. However, each one showed a different profile in the N/C interaction assay. When p.Gln799Glu and p.Cys807Phe were analyzed in combination, transactivation activities <10% in physiologic hormone conditions indicated an association with a CAIS phenotype. We conclude that the functional analysis elucidated the role of mutant ARs, giving clues for the molecular mechanisms associated with different clinical AIS manifestations. Differences in hormone-dependent profiles may provide a basis for the response to treatment in each particular case.